Substrate Cycling in Energy Metabolism
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00361751|
Recruitment Status : Completed
First Posted : August 9, 2006
Last Update Posted : February 15, 2010
Insulin resistance and hyperglycemia contribute to negative outcomes in burned patients. We will assess insulin sensitivity in traditional terms of glucose metabolism, and with regard to the responsiveness of both muscle and liver protein metabolism, in severely burned patients. Plasma free fatty acid (FFA) and tissue TG levels will be manipulated via inhibition of peripheral lipolysis with nicotinic acid or activation of plasma lipoprotein lipase activity with heparin, stimulation of tissue fatty acid oxidation and thus reduction of tissue TG with the peroxisome proliferate-activated receptor (PPAR) alpha agonist fenofibrate. Methodological approaches will include stable isotope tracer techniques to quantify kinetic responses of protein, glucose and lipid metabolism in vivo, quantification of intracellular stores of TG and glycogen by means of magnetic resonance spectroscopy (MRS), as well as quantitative analysis of tissue levels of active products of fatty acids, key intermediates of the insulin signaling pathway, glycogen, the enzyme activities of citrate synthase and glycogen synthase and the activity of the muscle mitochondria. These studies will clarify the physiological and clinical significance of the alterations of tissue lipid metabolism that occur after burn injury, thereby forming the basis for new therapeutic approaches not only in this specific clinical condition but in other clinical circumstances in which hepatic and/or muscle TG is elevated.
We will investigate the general hypothesis that the accumulation of intracellular TG in liver and muscle either directly causes insulin resistance in those tissues or serves as an indictor of the intracellular accumulation of active fatty acid products, such as fatty acyl CoA and diacylglycerol, which in turn disrupt insulin action.
The following specific hypotheses will be investigated:
- Intracellular TG is elevated in both muscle and liver in severely burned patients. The reduction of the fat in the liver and the insulin resistance will improve clinical outcomes, glucose and protein metabolism.
- The insulin signaling pathway, as reflected by phosphoinositol-3-kinase (PI3K) and PKC activity, is impaired in tissues with elevated TG.
- Fatty acids, or their active intracellular products, are the direct inhibitors of insulin action, rather than the tissue TG itself.
|Condition or disease||Intervention/treatment||Phase|
|Burns Insulin Resistance||Drug: fenofibrate||Phase 2|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||40 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Phase 2 Trial to Examine the Metabolic Effects of Fenofibrate in Burned Patients|
|Study Start Date :||May 2003|
|Actual Study Completion Date :||May 2005|
- Daily Plasma Glucose
- Insulin stimulated glucose uptake
- Hepatic fat concentration
- Muscle fat concentrations and species
- Muscle insulin signalling
- Muscle mitochondrial function
- Muscle mitochondrial enzyme activity
- Hepatic protein production
- Muscle protein balance
- Whole Body palmitate oxidation
- FFA release/balance
- Resting Energy Expenditure
- Body Mass Composition
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00361751
|United States, Texas|
|Shriners Hospital for CHildren|
|Galveston, Texas, United States, 77550|
|Principal Investigator:||Robert R Wolfe, PhD||UTMB/University of Arkansas|